Pick · 5.0% · large · Health Care · last 109.62
Entry 104.00–107.50 · Stop 101.00 · Target 122.00 · Buy ≈ 24 shares (≈ $2,631 at 109.62)
Thesis (long, position, conviction 66)
Bull: Halozyme is compounding at an unusually high rate for a large-cap health-care name: Q2 2026 revenue grew 47.7% y/y to $481M, operating income rose to $287.7M (60% margin) and diluted EPS jumped to $1.90 from $1.33 (F-HALO-1 through F-HALO-4). Full-year 2025 operating cash flow was already $651.6M, and the company generated $421M of operating cash flow in just the first half of 2026 (F-HALO-5, F-HALO-7), funding a step-up in capital return: the prior $750M buyback was completed and replaced with a new $1.0B authorization through 2028 (F-HALO-8). Sell-side sentiment is uniformly positive (13 buy/strong-buy vs. 3 hold, zero sells, F-HALO-12). The October 8 Dutch court ruling barring Merck from selling subcutaneous Keytruda in eight European countries is a meaningful near-term tailwind for Halozyme's ENHANZE royalty stream tied to that product, and the stock's 44.6% three-month return and 41pp of relative strength vs. SPY (F-HALO-11, rs_vs_spy_3m) show the market is still digesting it. Technically the stock is in an uptrend (price above 50- and 200-day MAs of $106.76 and $79.84) with RSI at a neutral 51.5 — not overbought — and sitting only 4.9% below its 52-week high, suggesting room to extend post-earnings (next report November 9).
Bear: The stock has already moved 44.6% in three months and sits just below its 20-day MA ($111.01 vs. $109.62 close), so much of the Merck-ruling optimism may already be priced in; a disappointing Q3 print or an adverse appeal in the Keytruda litigation could trigger a sharp mean-reversion toward the 50-day MA near $107 or lower. The September 17 pricing of $1.3B in 1.50% convertible notes due 2033 (F-HALO-9) adds leverage and sets up potential share dilution if the stock clears the $139.84 conversion price — a real possibility given the stock's momentum and only ~113.5M shares outstanding (F-HALO-13). Cash and marketable securities were only $231M at June 30, 2026 despite strong operating cash flow, partly because $332.7M was spent on buybacks in just six months (F-HALO-6, F-HALO-7) — an aggressive capital-return posture that leaves less cushion. Finally, the brief does not establish whether the European Keytruda ruling is final or under appeal, so the key bullish catalyst carries real headline risk in either direction.
Valuation: Using Q2 2026 diluted EPS of $1.90 and 113.5M shares, trailing four-quarter earnings power (even conservatively using the 2025 base of $316.9M net income, F-HALO-5) implies the stock trades in the high-teens to low-20s P/E range versus ~48% quarterly revenue growth and 60% operating margins — inexpensive relative to the growth and margin profile for a health-care royalty/drug-delivery business, assuming the Q2 beat is not a one-off milestone payment. The brief does not provide a clean normalized forward EPS or explicit FCF yield, so this view carries some uncertainty about how repeatable the Q2 operating leverage is; operating cash flow trends ($651.6M FY2025, $421M in H1 2026) support the cash-generative read-through. Net-net, valuation looks reasonable-to-cheap given growth, but the recent 44% rally has already compressed some of that discount.
Catalysts
2026-11-09: Q3 2026 earnings report expected to confirm continuation of revenue growth and margin trends seen in Q2
undated: Further developments in the European Keytruda subcutaneous patent dispute (appeal or expansion of the ruling) could extend or reverse the royalty-driven re-rating
Facts
F-HALO-1: Revenue for the quarter ended June 30, 2026 was $481.0 million, up approximately 47.7% from $325.7 million in the year-earlier quarter. (as of 2026-06-30)[E4678]
F-HALO-2: Operating income for the quarter ended June 30, 2026 was $287.7 million, compared with $202.4 million in the year-earlier quarter. (as of 2026-06-30)[E4678]
F-HALO-3: Net income for the quarter ended June 30, 2026 was $229.9 million, compared with $165.2 million in the year-earlier quarter. (as of 2026-06-30)[E4678]
F-HALO-4: Diluted EPS for the quarter ended June 30, 2026 was $1.90, compared with $1.33 in the year-earlier quarter. (as of 2026-06-30)[E4678]
F-HALO-5: For calendar 2025, revenue was $1.397 billion, operating income was $469.0 million, net income was $316.9 million, and operating cash flow was $651.6 million. (as of 2025-12-31)[E5424]
F-HALO-6: At June 30, 2026, cash, cash equivalents and marketable securities totaled $231.0 million; management said it expected those resources to fund operations for at least the next 12 months. (as of 2026-06-30)[E5437]source
F-HALO-7: In the six months ended June 30, 2026, operating activities provided $421.0 million of cash, while the company repurchased $332.7 million of common stock. (as of 2026-06-30)[E5437]source
F-HALO-8: The company reported completing its prior $750 million share-repurchase authorization in the second quarter of 2026 and authorizing a new program of up to $1.0 billion through December 31, 2028. (as of 2026-06-30)[E5437]source
F-HALO-9: On September 17, 2026, Halozyme announced pricing of $1.3 billion of 1.50% convertible senior notes due 2033, with an initial conversion price of approximately $139.84 per share. (as of 2026-09-17)[E5436]source
F-HALO-10: HALO closed at $109.62 on October 13, 2026, below its 20-day moving average of $111.01 and above its 50-day and 200-day moving averages of $106.76 and $79.84, respectively. (as of 2026-10-13)[E4677]
F-HALO-11: HALO's reported three-month return through October 13, 2026 was 44.58%. (as of 2026-10-13)[E4677]
F-HALO-12: The analyst recommendation tally for September 2026 was 3 strong buy, 10 buy, 3 hold, and no sell or strong sell recommendations. (as of 2026-09-01)[E4703]
F-HALO-13: Halozyme's second-quarter 2026 Form 10-Q reported 113.498 million common shares outstanding as of July 31, 2026. (as of 2026-07-31)[E5438]source
Critic
O2 (major): The underlying thesis treats a prohibition on sales of a royalty-generating product as a royalty tailwind. Accepted: Legal tailwind dropped; HALO's case now rests solely on Q2 fundamentals, weight cut to 5%, conviction to 60.
O3 (major): The stated 2.4-to-1 reward/risk does not apply near the proposed entry ceiling. Accepted: Entry zone moved to 104-107.5, restoring about 2.2x reward-to-risk and limiting the fill to a pullback.
What would change the view
Confirmation that the Merck Keytruda ruling has been stayed, appealed successfully by Merck, or narrowed in scope
Q3 2026 revenue growth below roughly 25-30% y/y, suggesting Q2's 47.7% growth was a one-time milestone-driven spike rather than a trend
Cash and marketable securities falling further while buybacks continue, signaling balance-sheet strain post convertible-note issuance
A daily close below $101 (near the 2x-ATR stop), invalidating the current uptrend structure
Data quality
Quality score 96/100.
Gap: The quote block is timestamped October 14, 2026, after the supplied as-of date of October 13, 2026, and reports $116.70 versus the October 13 daily close of $109.62; the quote was excluded.
Gap: The supplied pack and retrieved filing excerpts do not establish the final outcome or appeal status of the reported European Keytruda patent ruling.
Red flag: The $1.3 billion convertible-note issuance adds debt obligations and potential dilution upon conversion; the initial conversion price was approximately $139.84 per share (E5436).